SanBio Co. Ltd. | Income Statement

Fiscal year is February-January. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Sales/Revenue
204
3,229
1,175
950
491
742
Cost of Goods Sold (COGS) incl. D&A
4
6
-
44
54
-
Gross Income
200
3,224
-
906
437
-
SG&A Expense
784
975
2,286
2,838
4,815
4,357
EBIT
584
2,249
1,125
1,932
4,378
3,734
Unusual Expense
-
-
18
-
9
1
Non Operating Income/Expense
5
15
13
199
499
894
Interest Expense
-
5
18
43
93
93
Pretax Income
589
2,228
1,172
2,166
3,939
2,919
Income Tax
-
492
184
331
1
1
Consolidated Net Income
589
1,736
988
1,835
3,940
2,921
Net Income
589
1,736
988
1,835
3,940
2,921
Net Income After Extraordinaries
589
1,736
988
1,835
3,940
2,921
Net Income Available to Common
589
1,736
988
1,835
3,940
2,921
EPS (Basic)
15.41
44.31
22.67
40.88
86.85
60.17
Basic Shares Outstanding
38
39
44
45
45
49
EPS (Diluted)
15.41
44.31
22.67
40.88
86.85
60.17
Diluted Shares Outstanding
38
39
44
45
45
49
EBITDA
580
2,254
1,111
1,905
4,325
3,697
Non-Operating Interest Income
-
-
2
9
25
13

About SanBio Co.

View Profile
Address
St. Luke Tower, 28/F
Tokyo Tokyo 104
Japan
Employees -
Website http://www.sanbio.jp
Updated 07/08/2019
SanBio Co., Ltd. engages in the development and sale of regenerative cells pharmaceuticals. It also provides regenerative therapies for neurological disorders that include stroke, traumatic brain injury, eye diseases, and Parkinson's disease. The company was founded by Keita Mori and Toru Kawanishi in February 2001 and is headquartered in Tokyo, Japan.